Oncodesign Services and Nexus BioQuest Form Integrated Preclinical Partnership
- Oncodesign Services (Dijon, France) and Nexus BioQuest (Bristol, UK) have partnered to offer combined in vivo oncology and in vitro immunology preclinical services, eliminating the need for biotech sponsors to manage separate vendor relationships.
- Oncodesign brings AAALAC-accredited BSL1/2/3 pharmacology infrastructure including radiopharmaceuticals, imaging, and IND-enabling services; Nexus BioQuest contributes human primary cell-based assay platforms for immuno-oncology and autoimmunity across small molecules, biologics, vaccines, and cell therapies.
- The integrated model targets emerging biotech companies lacking resources to evaluate and manage multiple specialist CROs, particularly for immuno-oncology, cell therapy, and next-generation biologics programs requiring complementary in vivo and in vitro expertise.
Operational Impact
Oncodesign Services' integrated partnership with Nexus BioQuest consolidates preclinical oncology and immunology capabilities, reducing vendor management overhead for sponsors and potentially increasing contract value per relationship for both CROs.
Source: PharmaSource RSS
Quotient Sciences Demonstrates AI-Driven Formulation Selection in Clinical Trial
- Quotient Sciences' proprietary AI algorithm selected modified-release formulation compositions and doses in a live clinical trial, reaching pharmacokinetic targets within three dosing periods.
- The algorithm screened one-third fewer formulations than conventional methods in prior laboratory work and learned human pharmacokinetic relationships quickly enough to potentially reduce clinical testing timelines for future modified-release programs.
Operational Impact
Quotient Sciences' demonstrated AI-driven formulation optimization may reduce clinical trial cycles and screening burden for sponsors developing modified-release drugs, differentiating the CRDMO's early-development service offering.
Source: Contract Pharma Breaking News RSS